HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma.

Abstract
Long non-coding RNAs (lncRNAs) comprise an integral part of the eukaryotic transcriptome. Alongside proteins, lncRNAs modulate lncRNA-based gene signatures of unstable transcripts, play a crucial role as antisense lncRNAs to control intracellular homeostasis and are implicated in tumorigenesis. However, the role of genomic instability-associated lncRNAs in low-grade gliomas (LGG) has not been fully explored. In this study, lncRNAs expression and somatic mutation profiles in low-grade glioma genome were used to identify eight novel mutant-derived genomic instability-associated lncRNAs including H19, FLG-AS1, AC091932.1, AC064875.1, AL138767.3, AC010273.2, AC131097.4 and ISX-AS1. Patients from the LGG gene mutagenome atlas were grouped into training and validation sets to test the performance of the signature. The genomic instability-associated lncRNAs signature (GILncSig) was then validated using multiple external cohorts. A total of 59 novel genomic instability-associated lncRNAs in LGG were used for least absolute shrinkage and selection operator (Lasso), single and multifactor Cox regression analysis using the training set. Furthermore, the independent predictive role of risk features in the training and validation sets were evaluated through survival analysis, receiver operating feature analysis and construction of a nomogram. Patients with IDH1 mutation status were grouped into two different risk groups based on the GILncSig score. The low-risk group showed a relatively higher rate of IDH1 mutations compared with patients in the high-risk group. Furthermore, patients in the low-risk group had better prognosis compared with patients in the high-risk group. In summary, this study reports a reliable prognostic prediction signature and provides a basis for further investigation of the role of lncRNAs on genomic instability. In addition, lncRNAs in the signature can be used as new targets for treatment of LGG.
AuthorsAierpati Maimaiti, Xixian Wang, Yinan Pei, Nuerbiye Nuermaimaiti, Abudireheman Tuersunniyazi, Yaeraili Abula, Zhaohai Feng, Lei Jiang, Xin Shi, Maimaitijiang Kasimu
JournalAging (Aging (Albany NY)) Vol. 13 Issue 11 Pg. 15164-15192 (06 03 2021) ISSN: 1945-4589 [Electronic] United States
PMID34081618 (Publication Type: Journal Article, Validation Study)
Chemical References
  • Biomarkers, Tumor
  • FLG protein, human
  • Filaggrin Proteins
  • RNA, Long Noncoding
  • RNA, Messenger
  • Isocitrate Dehydrogenase
  • IDH1 protein, human
Topics
  • Adult
  • Area Under Curve
  • Biomarkers, Tumor (genetics)
  • Brain Neoplasms (genetics, pathology)
  • Female
  • Filaggrin Proteins
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Genomic Instability
  • Glioma (genetics, pathology)
  • Humans
  • Isocitrate Dehydrogenase (genetics)
  • Kaplan-Meier Estimate
  • Male
  • Multivariate Analysis
  • Mutation (genetics)
  • Neoplasm Grading
  • Prognosis
  • Proportional Hazards Models
  • RNA, Long Noncoding (genetics, metabolism)
  • RNA, Messenger (genetics, metabolism)
  • ROC Curve
  • Reproducibility of Results

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: